Trials / Completed
CompletedNCT03364153
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 121 (actual)
- Sponsor
- Astellas Pharma Global Development, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with autosomal recessive Stargardt disease 1 (STGD1).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | avacincaptad pegol | Intravitreal Injection |
| DRUG | Sham | Intravitreal Injection |
Timeline
- Start date
- 2018-01-12
- Primary completion
- 2025-03-31
- Completion
- 2025-03-31
- First posted
- 2017-12-06
- Last updated
- 2026-04-15
- Results posted
- 2026-03-12
Locations
41 sites across 8 countries: United States, France, Germany, Hungary, Israel, Italy, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03364153. Inclusion in this directory is not an endorsement.